Literature DB >> 8938763

Prediction of hemorrhagic complications after thrombolytic therapy for middle cerebral artery occlusion: value of pre- and post-therapeutic computed tomographic findings and angiographic occlusive site.

K Yokogami1, S Nakano, H Ohta, T Goya, S Wakisaka.   

Abstract

OBJECTIVE: To evaluate the usefulness of pre- and post-therapeutic computed tomographic (CT) findings in predicting hemorrhagic complications, we retrospectively examined 35 patients treated with intra-arterial thrombolytic therapy for middle cerebral artery (MCA) occlusion.
METHODS: The presence or absence of early CT findings (loss of the insular ribbon, obscuration of the lentiform nucleus, and cortical effacement) and the presence and location of extravasation of contrast medium were evaluated on pre- and post-therapeutic CT scans, respectively. According to the angiographic occlusive site, the patients were classified into the following three groups: Group 1 (n = 13), MCA trunk occlusion involved lenticulostriate arteries; Group 2 (n = 11), occlusion of the MCA trunk without involvement of the lenticulostriate arteries; Group 3 (n = 11), occlusion of a branch of the MCA. Hemorrhagic complications (hemorrhagic transformation and/or massive brain swelling) were evaluated by reviewing CT scans obtained 3 to 14 days after thrombolytic therapy.
RESULTS: No patient without extravasation (n = 17) showed hemorrhagic complications, and extravasation is the most useful finding in predicting hemorrhagic complications. There was significant correlation between extravasation and hemorrhagic complications (P < 0.01). In Groups 1 and 2, there was also significant correlation between early CT findings and hemorrhagic complications (P < 0.01), indicating that early CT findings are also useful in predicting hemorrhagic complications. In Group 1, 10 of 13 (76.9%) patients had both early CT findings and extravasation, and 6 of these 10 patients had hemorrhagic complications with clinical deterioration, suggesting the difficulty of thrombolytic therapy in this group. On the contrary, in Group 2, 8 of 11 (72.7%) patients had neither early CT findings nor extravasation and none of these 8 patients had hemorrhagic complications. In Group 3, however, early CT findings and extravasation had no correlation. Because the affected area was small in this group, it was difficult to evaluate cortical effacement. Although negative early CT findings did not always mean absence of extravasation and hemorrhagic complications in this group, the patients with hemorrhagic complications did not clinically deteriorate because of the small affected area.
CONCLUSION: Hemorrhagic complications could be predicted by evaluation of angiographic occlusive site and pre- and post-therapeutic CT findings.

Entities:  

Mesh:

Year:  1996        PMID: 8938763     DOI: 10.1097/00006123-199612000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  25 in total

1.  Intra-arterial thrombolysis.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  Hemorrhage/contrast staining areas after mechanical intra-arterial thrombectomy in acute ischemic stroke: imaging findings and clinical significance.

Authors:  G Parrilla; B García-Villalba; M Espinosa de Rueda; J Zamarro; E Carrión; F Hernández-Fernández; J Martín; R Hernández-Clares; A Morales; A Moreno
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

3.  Clinical significance of post-interventional cerebral hyperdensities after endovascular mechanical thrombectomy in acute ischaemic stroke.

Authors:  Omid Nikoubashman; Arno Reich; Mirco Gindullis; Katharina Frohnhofen; Rastislav Pjontek; Marc-Alexander Brockmann; Jörg B Schulz; Martin Wiesmann
Journal:  Neuroradiology       Date:  2013-12-05       Impact factor: 2.804

4.  Quantitative measurement of cerebral blood flow by (99m)Tc-HMPAO SPECT in acute ischaemic stroke: usefulness in determining therapeutic options.

Authors:  A Umemura; T Suzuka; K Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

5.  New insight into transient contrast enhancement on computed tomography after endovascular treatment of stroke.

Authors:  M U Antonucci; J Mocco; J A Bennett
Journal:  Interv Neuroradiol       Date:  2012-09-10       Impact factor: 1.610

6.  Combined direct percutaneous transluminal angioplasty and low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion.

Authors:  Takumi Yoneyama; Shinichi Nakano; Hirokazu Kawano; Tsutomu Iseda; Tokuro Ikeda; Tomokazu Goya; Shinichiro Wakisaka
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

7.  Correlation between Haemorrhagic Complications and CT Findings before and after Intra-arterial Reperfusion Therapy for Acute Middle Cerebral Artery Occlusion.

Authors:  S Nakano; S Wakisaka; H Kawano; T Yoneyama
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

8.  Temporal evolution of intraparenchymal hyperdensity after intra-arterial therapy in patients with ischemic stroke: optimal discrimination between hemorrhage and iodinated contrast.

Authors:  O Khalilzadeh; B Sabel; Y Sung; A Parikh; C M Phan; J Dinkel; A J Yoo; J Romero; R Gupta
Journal:  Clin Neuroradiol       Date:  2014-01-30       Impact factor: 3.649

9.  Differentiating intraparenchymal hemorrhage from contrast extravasation on post-procedural noncontrast CT scan in acute ischemic stroke patients undergoing endovascular treatment.

Authors:  Seyedmehdi Payabvash; Mushtaq H Qureshi; Shayaan M Khan; Mahnoor Khan; Shahram Majidi; Swaroop Pawar; Adnan I Qureshi
Journal:  Neuroradiology       Date:  2014-06-13       Impact factor: 2.804

10.  Contrast staining on CT after DSA in ischemic stroke patients progresses to infarction and rarely hemorrhages.

Authors:  Matthew R Amans; Daniel L Cooke; Maya Vella; Christopher F Dowd; Van V Halbach; Randall T Higashida; Steven W Hetts
Journal:  Interv Neuroradiol       Date:  2014-02-10       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.